Onesource Specialty Pharma Limited — M&A Activity 2025

Aug 4, 2025

Star 1, Opp IIM Bangalore, Bilekahalli, Cyber One, Unit No. 902, Sector 30A Bannergha�a Road, Bengaluru – Plot No - 4 & 6, Vashi, Navi Mumbai 560076, India 400703 India T: +91 80 6784 0738 F: +91 22 2789 2924 T: 91 22 2789 2942

==> picture [170 x 19] intentionally omitted <==

Date: August 04, 2025

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292 ISIN: INE013P01021	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ONESOURCE

Dear Sir/ Madam,

Sub: Update:

In-principle approval of the Board of Directors to evaluate acquisition of Sterile Injectable CDMO and CMO businesses of Steriscience Pte. Limited (“SteriScience SG”) and Brooks Steriscience Limited.

The Board of Directors at their meeting held today i.e., August 04, 2025 has given their in-principle approval to evaluate potential acquisition of the Sterile Injectable CDMO and CMO businesses of Steriscience and Carbapenem facility of Brooks Steriscience Limited.

The potential transaction, if finalised and consummated, will bring in the following facilities into OneSource:

• USFDA-approved sterile fill-finish manufacturing facility in Warsaw, Poland, with the ability to expand capacity for drug-device combination products for our global partners. This site serves marquee global players and several IP-led products.

• An integrated, state-of-the-art, USFDA-approved carbapenem facility in Vadodara, India operated under the name of Brooks Steriscience Limited.

Steriscience SG and Brooks Steriscience Limited are majorly owned directly/ indirectly by the Promoters of the Company.

Board has authorised the Management to undertake detailed evaluation of the potential transaction including suggesting optimal structure and present to the Audit Committee, Committee of Independent Directors and the Board of Directors.

Further, Board also authorised the Management to appoint Consultants, Advisors (Legal and Financial), Valuers, Merchant Bankers and such other intermediaries/ agencies as may be required to evaluate the potential transaction.

Company will make appropriate disclosures in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, post consideration and approval of the matter by the Board.

You are requested to kindly take the same on record.

For and on behalf of

OneSource Specialty Pharma Limited

Digitally signed by Trisha A Trisha A Date: 2025.08.04 19:24:42 +05'30'

Trisha A

Company Secretary and Compliance Officer Membership Number: A47635

OneSource Specialty Pharma Limited Formerly Stelis Biopharma Limited

info@onesourcecdmo.com | www.onesourcecdmo.com

CIN: L74140MH2007PLC432497